Singh, Dave http://orcid.org/0000-0001-8918-7075
Wedzicha, Jadwiga A.
Siddiqui, Salman
de la Hoz, Alberto
Xue, Wenqiong
Magnussen, Helgo
Miravitlles, Marc
Chalmers, James D.
Calverley, Peter M. A.
Funding for this research was provided by:
Boehringer Ingelheim (N/A)
Article History
Received: 29 April 2020
Accepted: 6 August 2020
First Online: 17 September 2020
Ethics approval and consent to participate
: All studies were reviewed and received approval/favourable opinion from the local Institutional Review Board/Independent Ethics Committee and approval by the Competent Authority in each participating European Union member state and other regulatory authorities as required by local laws and regulations. All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
: Not applicable.
: DS reports personal fees from Apellis, Cipla, Genentech, Peptinnovate and Skyepharma, and grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Theravance and Verona, outside the submitted work. JAW reports grants from GlaxoSmithKline, Johnson and Johnson, AstraZeneca, Boehringer Ingelheim and Novartis, and other from Novartis, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline, outside the submitted work. SS reports personal fees and other from Boehringer Ingelheim and Chiesi, and personal fees from GlaxoSmithKline, AstraZeneca, ERT Medical, Owlstone Medical, Mundipharma and Novartis, outside the submitted work. AdlH and WX are both employees of BI. HM reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis and ndd, during the conduct of the study. MM reports personal fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, AstraZeneca, Teva, Kamada, Zambon, Grifols, Novartis, Gebro Pharma, CSL Behring, Cipla, MedImmune, Mereo BioPharma and Sandoz, and grants from GlaxoSmithKline and Grifols, outside the submitted work. JDC reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, Zambon, Insmed, Grifols, Novartis and AstraZeneca, grants from Gilead, and personal fees from Napp, outside the submitted work. PMAC reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, Boehringer Ingelheim, Recipharm and Zambon, and personal fees and other from Boehringer Ingelheim, outside the submitted work.